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Abstract
Background
South Sudan is one of the most endemic countries for visceral leishmaniasis (VL), and is fre-
quently affected by large epidemics. In resource-limited settings, clinicians require a simple
clinical tool to identify VL patients who are at increased risk of dying, and who need special-
ised treatment with liposomal amphotericin B and other supportive care. The aim of this
study was to develop and validate a clinical severity scoring system based on risk factors for
death in VL patients in South Sudan.
Methods
A retrospective analysis was conducted of data from a cohort of 6,633 VL patients who were
treated in the Me´decins Sans Frontières (MSF) hospital in Lankien between July 2013 and
June 2015. Risk factors for death during treatment were identified using multivariable logis-
tic regression models, and the regression coefficients were used to develop a severity scor-
ing system. Sensitivity and specificity of score cut-offs were assessed by receiver operating
characteristic (ROC) analysis.
Results
In multivariable models, risk factors for death in adult VL patients were: anaemia (odds ratio
(OR) 4.46 (95% CI 1.58–12.6) for Hb <6g/dL compared with9g/dL), nutritional status (OR
4.84 (2.09–11.2) for BMI <13 kg/m2 compared with16 kg/m2), weakness (OR 4.20 (1.82–
9.73) for collapsed compared with normal weakness), jaundice (OR 3.41 (1.17–9.95)), and
oedema/ascites (OR 4.86 (1.67–14.1)). For children and adolescents the risk factors were:
age (OR 10.7 (6.3–18.3) for age <2 years compared with 6–18 years), anaemia (OR 7.76
(4.15–14.5) for Hb <6g/dL compared with9g/dL), weakness (OR 3.13 (22.8–105.2) for col-
lapsed compared with normal weakness), and jaundice (OR 12.8 (4.06–40.2)). Severity
scoring predictive ability was 74.4% in adults and 83.4% in children and adolescents.
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Conclusion
Our evidenced-based severity scoring system demonstrated sufficient predictive ability to
be operationalised as a clinical tool for rational allocation of treatment to VL patients at MSF
centres in South Sudan.
Author summary
Visceral leishmaniasis (VL), also known as kala-azar, is a neglected tropical disease caused
by a parasite (Leishmania) and transmitted to humans through the bite of a sandfly. South
Sudan is one of the highest endemic countries for VL, frequently affected by epidemics. In
South Sudan are different treatment options for VL available: the standard therapy given
on ambulatory bases by intramuscular injections for 17 days, and specialized treatment
for patients with severe VL, administered intravenously in a hospital over 12 days. In the
extremely resource limited context of South Sudan, the most optimal treatment to patients
with severe VL should be provided, but a rational use of drugs maintained. In this study,
we identified risk factors for death in VL patients of South Sudan, and based on these risk
factors we developed a severity scoring system. This severity scoring system will be a clini-
cal decision making tool for allocation of VL patients to the appropriate treatment and to
minimise the mortality of the VL patients in South Sudan.
Introduction
Visceral leishmaniasis (VL, or kala-azar) is a neglected tropical disease which is caused by the
obligate intracellular protozoa of the Leishmania donovani complex (L. donovani and L. infan-
tum) (1). In East Africa VL is caused by L. donovani, and is transmitted anthroponotically by
phlebotomine sandfly vectors [1].
VL targets the lymphatic and reticuloendothelial system, affecting spleen, liver, mucosa of
the small intestine and respiratory tract, bone marrow, lymph nodes and the other lymphoid
tissues, causing persistent fever, organomegaly, pancytopenia and wasting. Patients with VL
are severely immunocompromised, and death occurs from opportunistic or concomitant
infections, or from complications such as malnutrition, anaemia or bleeding. Without treat-
ment VL is typically fatal [1, 2].
South Sudan is one of the most endemic countries for VL, with an annual incidence of
7,400–14,200 cases [3]. The country has been affected by frequent large epidemics, often asso-
ciated with mass displacement due to armed conflict, and causing high mortality [4, 5].
Current first line treatment for VL in South Sudan is the pentavalent antimonial, sodium
stibogluconate (SSG), in combination with an aminoglycoside, paromomycin (PM). SSG/PM
is given on an ambulatory basis over 17 days with daily intramuscular injections [6, 7]. How-
ever, SSG is often poorly tolerated, and toxicity results in a significant incidence of serious
adverse events such as pancreatic, hepato- and nephrotoxicity, cardiotoxicity, gastro-intestinal
disorders and, in pregnant women, spontaneous abortion [8–11]. For this reason, SSG is con-
traindicated for specific patient groups (e.g. pregnant women or HIV co-infected) or in
patients with severe VL. These patients should be treated with liposomal amphotericin B
(AmBisome) [12]. AmBisome is much better tolerated but is much more expensive and
requires cold chain transportation, cool storage, intravenous administration, and hospitalisa-
tion for at least 12 days.
A severity scoring system for visceral leishmaniasis South Sudan
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These are major challenges in the resource limited context of South Sudan, meaning that
rational use of AmBisome is currently a key operational requirement. AmBisome needs to be
reserved for severely ill VL patients who are at high risk of dying or at risk of SSG intolerability
[12–14], whilst standard SSG/PM treatment can continue to be administered to patients with
uncomplicated VL [7]. In resource-limited settings, clinicians require a simple clinical tool to
identify VL patients who are at increased risk of dying, and who need specialised treatment
with liposomal amphotericin B and other supportive care.
The aim of this study was to develop an evidenced-based risk scoring system which could
be used as a clinical decision making tool in the field, to help clinicians decide whether a VL
patient requires intensive VL care and treatment with AmBisome or standard VL management
and less intensive monitoring. The risk scoring system would be based on risk factors for
death during treatment in a retrospective cohort of VL patients, and would be validated inter-
nally and against older cohorts of VL patients treated by MSF in South Sudan.
Methods
Ethics statement
This research fulfilled the exemption criteria set by the Me´decins Sans Frontières Ethical
Review Board for a posteriori analyses of routinely collected clinical data, and thus did not
require MSF ERB review. It was conducted with permission from the Medical Director of the
MSF Operational Centre Amsterdam. All data were anonymised before analysis.
Study design and data source
A retrospective analysis was conducted of routinely collected data from a cohort of 6,821 VL
patients who attended the hospital of Me´decins Sans Frontières (MSF) in Lankien, Jonglei
state, South Sudan during the VL outbreak between July 2013 and June 2015. The data were
stored in an electronic database, and included key dates, demographic, anthropometric, diag-
nostic and clinical characteristics of patients, treatment regime and outcome. Patients with
incomplete data and who defaulted from treatment were excluded from analyses. VL-HIV
coinfected patients were excluded because treatments and outcomes are different in this small
immunocompromised subgroup (during the study period the HIV/VL rate in Lankien was
only 0.15%).
Outcome
Our analysis was based on a binary outcome of died (during or immediately after treatment)
or survived treatment. “Survived” means that the patient was discharged after successful clini-
cal response to treatment: absence of fever, reduction of spleen and liver size, increased hae-
moglobin, restored appetite, and feeling well. Patients with an increased risk of treatment
failure or relapse (i.e. patients with a prior episode of VL, or patients with inadequate or doubt-
ful clinical response) require a negative parasitological test-of-cure by aspirate microscopy to
confirm cure of VL.
There is no systematic follow up of patients after discharge, because they return to areas
remote from the treatment centre. A defaulter was defined as a patient who did not complete
treatment, and had an unknown outcome.
Risk factors
The dataset included the following potential risk factors for death in VL: age (years), sex, pres-
ence/absence of jaundice, lymphadenopathy, oedema/ascites; prior episode/relapse of VL, Hb
A severity scoring system for visceral leishmaniasis South Sudan
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level (g/dL), spleen size (cm below the left costal margin), self-reported duration of illness
(months), and nutritional status (body mass index (BMI) in patients19years (kg/m2) and
weight for height Z scores (WHZ) in patients <19 years old). State of weakness, was defined as
‘normal weakness’ (non-severe); ‘severe weakness’ (if patient needs assistance in walking or, in
babies, if unable to sit up); or ‘collapse’ (if patient is unable to sit or drink or, in babies, if hypo-
tonic and unable drink unaided). All of these variables have been identified as risk factors for
death in earlier VL patient cohorts from South Sudan [2, 5, 15, 16].
Diagnosis
All patients presenting with a history of fever more than 2 weeks and splenomegaly and/or
lymphadenopathy and/or wasting (BMI<16 mg/m2 or <-2 Zscore) were considered VL sus-
pects and underwent further diagnostic evaluations. Patients without prior VL treatment his-
tory (suspect primary VL) were first screened using the rK39 rapid diagnostic test (IT-Leish,
Bio-Rad laboratories, USA) and a positive result confirmed VL. Those testing negative were
screened with the leishmania direct agglutination test (DAT, Royal Tropical Institute, Amster-
dam, The Netherlands) and a high titer (1:6400) confirmed VL. Those with an intermediate
DAT titer (1:800–1:3200) underwent tissue aspiration (spleen or lymph node) and positive
result confirmed VL. Patients with prior VL treatment history (suspect relapse VL) underwent
tissue aspiration and a positive result confirmed VL. A clinical diagnosis was made in patients
contra-indicated for spleen aspirate (i.e. severely anaemic, bleeding, pregnant or collapsed)
and didn’t have palpable lymph nodes or those with negative lymph node aspirate results but
with persistent strong VL clinical suspicion in the absence of differential diagnoses [17].
Treatment
The first line treatment was with SSG (20 mg/kg) in combination with PM (15 mg/kg) given
on an ambulatory basis over 17 days with daily intramuscular injections.
Specific patients groups with contra-indication for SSG (pregnant women, HIV co-
infected) or patients with known poor tolerability of SSG (age >45 years, severe VL) were
treated with AmBisome by 6 IV infusions of 5 mg/kg on alternate days. Treatment had started
without delay on the same day as confirmation of diagnosis.
If clinical and laboratory investigations confirm severe VL disease, specialised treatment
was started immediately. ‘Specialised treatment’ means besides AmBisome also rehydration,
aggressive antibiotic treatment (ceftriaxone IV), other supportive treatment (e.g. for malnutri-
tion), intensified monitoring and treatment of any suspected abnormality.
As the aim is to predict a patient’s prognosis at the time of diagnosis, the treatment was not
included in the analysis.
Statistical analysis
Risk factors. Univariate and multivariable logistic regression models were used to quan-
tify the associations of risk factors with death as odds ratios (ORs) with 95% confidence inter-
vals (CIs). Two prediction models were built: one with patients aged 19 years and older
(adults), and one with the patients younger than 19 years (defined as children and adoles-
cents). Variables were included in the multivariable analysis if they had a significance level of
p<0.2 in the univariate analysis, and backwards elimination was then used to build final pre-
diction models.
Derivation of the severity scoring system. The severity scoring system was developed
using a method described by Barquet et al, which is based on the Spiegelhalter-Knills Jones
method [18–20]. Regression coefficients (RCs) from the final multivariable prediction model
A severity scoring system for visceral leishmaniasis South Sudan
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were used to calculate a score for each level of each risk factor (by dividing each RC by the
smallest RC in the model and rounding up or down to the nearest integer). The reference level
of each categorical variable was scored as ‘0’. The severity score for an individual patient is the
sum of his/her severity scores for each risk factor; a higher score indicating higher risk of
death, i.e. more severe illness [18, 21]. Probabilities of death can be calculated for each severity
score, but the rounding up or down of each RC means that combinations of different levels of
risk factors can lead to the same severity score, i.e. for each severity score there is a range of
probabilities of death. The upper and lower limits of this range for each severity score was cal-
culated using the method described by Coura-Vital et al [22].
Discriminative ability of the risk scoring system. The discriminative (predictive) ability
of the severity scoring system was assessed using receiver operating characteristic (ROC) anal-
ysis [25, 26]. Discriminative ability was quantified by area under the curve (AUC), categorised
as: ‘no better than a random guess’ (AUC 0.5–0.6); ‘poor’ (AUC 0.6–0.7); ‘fair’ (AUC 0.7–0.8);
‘good’ (AUC 0.8–0.9) or ‘excellent’ (AUC 0.9–1.0) [23, 24].
Determination of severity score thresholds. ROC analysis was used to calculate the sen-
sitivity and specificity of different risk score thresholds [25, 26]. The optimum threshold can
be determined by considering the clinical and operational implications of the sensitivity and
specificity of different thresholds.
Validation. The severity scoring system was validated in three datasets from previous
studies in South Sudan: two from patients treated in Lankien during 1999–2002 (N = 708) and
during 2002–2005 (N = 1882), and one from patients treated in Malakal during 2002–2005
(N = 1757) [2, 15]. Validation was performed with the use of the Z test by comparing the pre-
dictive ability (AUC) of the severity scoring system across the datasets [27].
Statistical software. SPSS for Windows 23.0 and STATA/IC 14.0 were used for the statis-
tical analyses.
Results
Study population
The initial dataset included 6,821 VL patients. After excluding patients with incomplete data
(n = 8), HIV co-infection (n = 11), who defaulted from treatment (n = 159) or referred to
another non MSF facility (n = 10) the total sample size was 6,633. Of these, 3,631 (54.7%) were
male and 3,002 (45.3%) were female. Out of the 6,614 patients of whom the duration of illness
was known 6,087 (92%) presented within 1 month after onset of symptoms, and no patient
presented later than 6 months.
Of the 6,615 patients whose treatment regime was known, 5,149 patients were treated with
SSG/PM and 1,466 patients with AmBisome. The data comprised 4,931 (74.3%) children and
adolescents (aged < 19 years) and 1,702 (25.7%) adults (19 years). Mortality data was cap-
tured during the complete time of admission in the hospital, until discharge or death; the lon-
gest admission duration was 134 days. In total 6,447 patients (97.7%) survived and 186 (2.8%)
died during treatment; 33% (49/186) of the deaths occurred within 48 hours of admission.
The characteristics of patients in each age group who died compared with those who sur-
vived are shown in Table 1. Mortality in children and adolescents was 2.4% compared with
4.1% among adults (OR 1.78 (95% CI 1.32–2.41)).
Risk factors in adults
Univariate analysis showed that age, Hb, state of weakness, nutritional status, jaundice, and
oedema/ascites were strongly associated with VL mortality (Table 2): patients >45 years old
had 3.4-fold higher odds of death (OR 3.42 (95% CI 1.64–7.16)) compared with patients aged
A severity scoring system for visceral leishmaniasis South Sudan
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18–25 years; patients in a state of collapse were 8 times more likely to die (OR 7.80 (95% CI
3.66–16.6)) compared with patients who arrived in a ‘normal’ state of weakness; Hb levels <
6g/dL increased the odds of dying almost 9-fold (OR 8.67 (95% CI 3.32–22.6)) compared with
Table 1. Characteristics of the study population by outcome (survived or died).
Adults (patients19 years old) Ch Children and Adolescents (patients <19 years old)
Variable Died n = 70
(4.1%)
Survived n = 1632
(95.9%)
Died n = 116
(2.4%)
Survived n = 4815
(97.5%)
Age, years
18–25 11 (2.2) 493 (97.8) 6–18 22 (0.7) 2949 (99.2)
26–35 20 (3.2) 602 (96.8) 2–5 37 (2.5) 1424 (97.5)
36–45 17 (6.4) 247 (93.6) < 2 57 (11.4) 442 (88.6)
> 45 22 (7.1) 290 (92.9)
Nutrition status BMI, kg/m2 WHZ
 16 14 (1.7) 806 (98.3) >-2 27 (2.3) 1137 (97.7)
14.5–15.9 25 (5.1) 468 (94.9) -2 35 (2.1) 1619 (97.9)
13–14.4 18 (6.5) 259 (93.5) -3 32 (1.3) 1652 (98.7)
< 13 13 (11.6) 99 (88.4) -4 21 (6.1) 323 (93.9)
Sex
male 42 (4.4) 915 (95.6) male 59 (2.2) 2615 (97.8)
female 28 (3.9) 717 (96.1) female 57 (2.5) 2200 (97.5)
State of weakness
normal
weakness
36 (2.6) 1345 (97.4) normal
weakness
83 (1.8) 4563 (98.2)
severe
weakness
24 (9.1) 239 (90.9) severe
weakness
28 (10.5) 239 (89.5)
collapse 10 (17.2) 48 (82.8) collapse 5 (41.7) 7 (58.3)
Hb, g/Dl
 9 37 (3.1) 1174 (96.9)  9 25 (1.0) 2562 (99.0)
7.5–8.9 17 (5.2) 310 (94.8) 7.5–8.9 29 (2.1) 1352 (97.9)
6–7.4 10 (7.4) 126 (92.6) 6–7.4 34 (4.3) 749 (95.7)
< 6 6(21.4) 22 (79.6) < 6 28 (15.6) 151 (84.3)
Duration of illness,
months
= 1 49 (3.9) 1195 (96.1) = 1 88 (2.3) 3714 (97.7)
< 1 12 (4.3) 268 (95.7) < 1 24 (3.2) 737 (96.8)
 2 9 (5.2) 164 (94.8)  2 4 (1.1) 350 (98.9)
Jaundice no 64 (3.8) 1613 (96.2) no 111 (2.3) 4790 (97.7)
yes 6 (24.0) 19 (76.0) yes 5 (17.9) 23 (82.1)
Oedema/ascites no 64 (3.8) 1610 (96.2) no 110 (2.3) 4766 (97.8)
yes 6 (21.4) 22 (79.6) yes 6 (10.9) 49 (89.1)
Lymphadenopathy no 20 (5.6) 337 (94.4) no 37 (4.0) 898 (96.0)
yes 50 (3.7) 1290 (96.3) yes 79 (2.0) 3907 (98.0)
Prior episode VL 0 61 (4.0) 1475 (96.0) 0 99 (2.2) 4347 (97.8)
1 or more 9 (5.4) 157 (94.6) 1 or more 17 (3.5) 468 (96.5)
Spleen size, cm
< 1 31 (4.9) 596 (95.1) < 1 40 (2.7) 1459 (97.3)
1–4 21 (4.0) 502 (96.0) 1–4 50 (2.5) 1936 (97.5)
5–7 10 (3.7) 262 (96.3) 5–7 15 (1.8) 803 (98.2)
>7 8 (2.9) 268 (97.1) >7 11 (1.8) 609 (98.2)
https://doi.org/10.1371/journal.pntd.0005921.t001
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levels9g/dL; and BMI<13 kg/m2 was associated with 7.6-fold higher odds of death (OR 7.56
(95% CI 3.45–16.6)) compared with BMI 16 kg/m2. Presence of jaundice and oedema/ascites
increased the odds of dying 8-fold (OR 7.95 (95% CI 3.07–20.6)) and almost 7-fold (OR 6.87
(95% CI 2.69–17.5)), respectively. Sex, lymphadenopathy, prior episode VL, duration of illness,
and spleen size were not associated with risk of death.
The effects of Hb, state of weakness, nutritional status, jaundice, and oedema/ascites were
reduced by mutual adjustment, and age was eliminated from the final prediction model
(Table 2). In this model, patients in a state of collapse were 4 times more likely to die (OR 4.20
Table 2. Risk factors for death among adult patients (19 years old).
Variable (n = 1,702) Category Univariate logistic regression Final prediction model
Crude ORa (95% CIb) P-valuec RCd Adjusted OR (95%CI) P–valuec
Sex male 0.52
female 0.85(0.52–1.39)
Age, years 18–25 0.002
26–35 1.50 (0.71–3.15)
36–45 3.10 (1.43–6.73)
> 45 3.42 (1.64–7.16)
State of weakness normal weakness < 0.001
severe weakness 3.76 (2.20–6.41) 0.90 2.45 (1.39–4.33) 0.002
collapse 7.80 (3.66–16.6) 1.44 4.20 (1.82–9.73) 0.001
BMI, kg/m2  16 < 0.001
14.5–15.9 3.08 (1.58–5.98) 0.96 2.60 (1.32–5.14) 0.006
13–14.4 4.00 (1.96–8.16) 1.02 2.78 (1.31–5.91) 0.008
< 13 7.56 (3.45–16.6) 1.58 4.84 (2.09–11.2) < 0.001
Hb, g/dL  9 < 0.001
7.5–8.9 1.74 (0.97–3.14) 0.07 1.08 (0.57–2.03) 0.82
6–7.4 2.52 (1.23–5.19) 0.42 1.52 (0.70–3.30) 0.29
< 6 8.67 (3.32–22.6) 1.50 4.46 (1.58–12.6) 0.005
Oedema/ascites no < 0.001 0.004
yes 6.87 (2.69–17.5) 1.58 4.86 (1.67–14.1)
Jaundice no < 0.001 0.025
yes 7.95(3.07–20.6) 1.23 3.41 (1.17–9.95)
Lymphadenopathy no 0.12
yes 0.65(0.38–1.11)
Prior episode VL 0 0.37
1 or more 1.39 (0.68–2.85)
Duration of illness, months = 1 0.73
< 1 1.09 (0.57–2.08)
 2 1.34 (0.65–2.78)
Spleen size, cm < 1 0.53
1–4 0.80 (0.46–1.42)
5–7 0.73 (0.35–1.52)
>7 0.57 (0.26–1.27)
a OR indicates odds ratio
b CI indicates confidence interval
c P value from Chi squared test
d RC indicates (unexponentiated) regression coefficient
https://doi.org/10.1371/journal.pntd.0005921.t002
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(95% CI 1.82–9.73)) compared with patients who arrived in a ‘normal’ state of weakness; Hb
levels <6g/dL increased the odds of dying 4.5-fold (OR 4.46 (95% CI 1.58–12.6)) compared
with levels9g/dL; and BMI <13 kg/m2 was associated with almost 5-fold higher odds of
death (OR 4.84 (95% CI 2.09–11.2)) compared with BMI 16 kg/m2. Presence of jaundice
and oedema/ascites increased the odds of dying >3-fold (OR 3.41 (95% CI 1.17–9.95)) and
almost 5-fold (OR 4.86 (95% CI 1.67–14.1)), respectively.
Risk factors in children and adolescent
The univariate analyses of children and adolescents showed that age, Hb, state of weakness,
jaundice, oedema/ascites and WHZ were strongly associated with VL mortality (Table 3).
Table 3. Risk factors for death among child and adolescent patients (<19 years old).
Univariate logistic regression Final prediction model
Variable (n = 4,931) Category Crude ORa (95% CIb) Pc value RCd Adjusted OR (95%CI) P valuec
Sex male 0.46
female 1.15 (0.79–1.66)
Age, years 6–18 < 0.001
2–5 3.48 (2.05–5.93) 0.98 2.67 (1.55–4.61) < 0.001
<2 17.29 (10.46–28.6) 2.37 10.74 (6.31–18.3) < 0.001
State of weakness normal weakness < 0.001
severe weakness 6.44 (4.12–10.1) 0.92 2.53 (1.53–4.18) < 0.001
state of collapse 39.27(12.21–126.3) 3.13 22.82 (4.95–105.2) < 0.001
WHZ > -2 < 0.001
= -2 0.91 (0.55–1.51)
= -3 0.87 (0.49–1.37)
= -4 2.74 (1.58–4.90)
Hb, g/dL  9 < 0.001
7.5–8.9 2.20 (1.28–3.77) 0.57 1.77 (1.02–3.08) 0.044
6–7.4 4.65 (2.76–7.85) 1.02 2.77 (1.59–4.82) < 0.001
< 6 19.00 (10.81–33.4) 2.05 7.76 (4.15–14.5) < 0.001
Oedema/ascites no <0.001
yes 5.31 (2.25–12.7)
Jaundice no < 0.001 < 0.001
yes 9.38 (3.50–25.2) 2.55 12.77 (4.06–40.2)
Lymphadenopathy no < 0.001
yes 0.49 (0.33–0.73)
Prior episode VL 0 0.08
1 or more 1.60 (0.94–2.69)
Duration of illness, months = 1 0.12
< 1 1.37 (0.87–2.17)
 2 0.48 (0.18–1.32)
Spleen size, cm < 1 0.44
1–4 0.94 (0.17–1.44)
5–7 0.68 (0.37–1.24)
>7 0.66 (0.34–1.29)
a OR indicates odds ratio
b CI indicates confidence interval
c P value from Chi squared test
d RC indicates (unexponentiated) regression coefficient
https://doi.org/10.1371/journal.pntd.0005921.t003
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Patients < 2 years old had>17-fold higher odds of death (OR 17.3 (95% CI 10.5–28.6))
compared with patients aged 6–18 years; patients in a state of collapse were 39 times more
likely to die (OR 39.3 (95% CI 12.2–126.3)) compared with patients who arrived in a ‘normal’
state of weakness; Hb levels <6g/dL increased the odds of dying 19-fold (OR 19.0 (95% CI
10.8–33.4)) compared with levels9g/dL; and WHZ<-4 was associated with almost 3-fold
higher odds of death (OR 2.74 (95% CI 1.58–4.90)) compared with WHZ > -2. Presence of
jaundice and oedema/ascites increased the odds of dying >9-fold (OR 9.38 (95% CI 3.50–
25.2)) and>5-fold (OR 5.31 (95% CI 2.25–12.7)), respectively.
For patients with lymphadenopathy, the odds of dying reduced by half. (OR 0.49 (95% CI
0.33–0.73) Sex, prior episode VL, and spleen size were not associated with risk of death. Dura-
tion of illness did not have sufficient cases for analyses.
The effects of age, Hb, state of weakness and jaundice were reduced by mutual adjustment,
and lymphadenopathy, nutritional status and oedema/ascites were eliminated from the final
prediction model (Table 3). In this model, patients < 2 years old had almost 11-fold higher
odds of death (OR 10.7 (95% CI 6.31–18.26)) compared with patients aged 6–18 years; patients
in a state of collapse were almost 23 times more likely to die (OR 22.8 (95% CI 4.95–105.2))
compared with patients who arrived in a ‘normal’ state of weakness; Hb levels <6g/dL in-
creased the odds of dying nearly 8-fold (OR 7.76 (95% CI 4.15–14.5)) compared with levels
9g/dL; and presence of jaundice increased the odds of dying 3.4-fold (OR 3.41 (95% CI 1.17–
9.95)).
Severity scoring system
The scores for each variable in the final prediction model are shown in Table 4, and the range
of probabilities for each score (due to rounding up or down of regression coefficients) are pre-
sented in Table 5. For adults, probability of death exceeded 10% for risk scores3 (6.1% (104/
1695) of adults); in children and adolescents, the threshold for exceeding a 10% probability of
death was a score6 (6.8% (339/4921) of children).
Table 4. Severity scoring for adults ( 19 years), and children and adolescents (< 19 years).
Severity Score
Variable Category Adults Children and adolescents
State of weakness normal weakness 0 0
severe weakness 1 2
state of collapse 2 5
Hb, g/dL  9.0 0 0
7.5–8.9 0 1
6.0–7.4 0 2
< 6.0 2 4
BMI, kg/m2  16 0
14.5–15.9 1
13.0–14.4 1
< 13 2
Jaundice not present 0 0
present 1 4
Oedema/ascites not present 0
present 2
Age, years 6–18 0
2–5 2
< 2 4
https://doi.org/10.1371/journal.pntd.0005921.t004
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For the severity scoring of the adults the classification matrix resulted in 80.8% correctly
predicted deaths. The AUC of the severity scores of the adults gave an overall predictive per-
formance of 74.4% (95 CI 68.0%-81.0%), indicating ‘fair’ predictive ability (Fig 1). For children
and adolescents, the classification matrix showed 80.6% correctly predicted. The AUC was
83.4% (95% CI 78.0%-86.8), interpreted as ‘good’ predictive ability (Fig 2). Sensitivity >55%
required a score2 in adults (sensitivity 57%, specificity 82%) and5 in children and adoles-
cents (sensitivity 64%, specificity 91%). Sensitivity >75% required a score1 in adults (sensi-
tivity 86%, specificity 44%) and4 in children and adolescents (sensitivity 75%, specificity
81%) (Table 6).
Table 5. Probabilities of deatha at each score for adults ( 19 years), and children and adolescents (< 19 years)b.
Adults Children and adolescents
Probability of death Probability of death
Severity
score
All cases (n) Observed case fatality
(n)
Lower limit Upper limit All cases (n) Observed case fatality
(n)
Lower limit Upper limit
0 719 10 1.2% 1.4% 1712 8 0.4% 0.5%
1 640 20 2.9% 4.0% 745 6 0.7% 0.7%
2 232 19 4.9% 10.3% 1001 9 1.0% 1.1%
3 77 13 11.8% 22.1% 450 6 1.8% 2.0%
4 21 6 18.6% 35.9% 506 13 2.7% 5.0%
5 6 2 37.3% 57.9% 168 17 4.8% 8.6%
6 - - 52.5% 71.4% 219 26 7.2% 14.3%
7–8 - - 74.2% 89.5% 95 20 17.8% 36.1%
9–10 - - 94.8% 94.8% 19 7 37.5% 47.1%
11–17 - - - - 6 4 46.1% 99.0%
aLow risk (green) <3% probability of death; Moderate risk (yellow) 3–10% probability of death; High risk (red) >10% probability of death.
b The number of cases in this table (adults N = 1695, children/adolescents N = 4921) are slightly lower than shown in Table 1 (adults N = 1702, children/
adolescents N = 4931) due to missing data for some of the predictive variables.
https://doi.org/10.1371/journal.pntd.0005921.t005
Fig 1. Area under the curve for adults scoring.
https://doi.org/10.1371/journal.pntd.0005921.g001
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Validation
External validation of the scoring for adults with the Lankien datasets of 1999–2002, 2002–
2005 and the Malakal dataset of 2002–2005 yielded AUC of 72.2%, 79.5% and 71.2%, respec-
tively. Discriminative ability did not differ significantly across the four datasets (p = 0.48). For
children and adolescents, corresponding AUC were 72.2%, 82.8% and 76.6%, with only very
weak evidence of a difference in discriminative ability across the three datasets (p = 0.13).
Discussion
In this study, the risk factors for death in VL patients in South Sudan during the VL epidemic
from 2013 to 2015 were analysed. Significant risk factors for adult patients were nutritional sta-
tus (BMI), Hb, weakness status, jaundice and oedema/ascites. In children and adolescents, the
Fig 2. Area under the curve for children and adolescents scoring.
https://doi.org/10.1371/journal.pntd.0005921.g002
Table 6. Performance of the severity scoring for prediction of death in VL patients in South Sudan.
Severity score Adults Children and adolescents
Sensitivity Specificity Sensitivity Specificity
0 100% 0.0% 100% 0.0%
1 85.7% 43.7% - -
2 57.1% 81.8% 87.9% 50.8%
3 30.0% 94.9% 80.2% 71.5%
4 11.4% 98.8% 75.0% 80.7%
5 2.9% 99.8% 63.8% 91.0%
6 0.0% 100% 49.1% 94.1%
7 0.0% 100% 26.7% 98.1%
8 0.0% 100% 25.0% 98.5%
9–10 0.0% 100% 9.5% 99.8%
11 - - 3.4% 100%
12 - - 2.6% 100%
13 - - 1.7% 100%
14 - - 0.0% 100%
https://doi.org/10.1371/journal.pntd.0005921.t006
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risk factors were age, Hb, weakness status and jaundice. Using these risk factors, an evidence-
based clinical severity scoring system was developed that may be able to determine reliably
and easily a patient’s risk of dying, thereby enhancing the rational use of more costly and com-
plex VL treatments. The overall accurate predictive ability of this severity scoring system was
confirmed by external validation in other data from the same setting.
VL treatment effect was not analysed, because in observational studies indications for treat-
ment are usually not standardised, and confounding by indication could lead to bias. More-
over, as the aim is to predict a patient’s prognosis at the time of diagnosis, the treatment
should not be included.
In operationalising a risk scoring system, erring towards a higher sensitivity over a lower
specificity would mean that >28% of child and> 56% of adult patients should receive special-
ised VL care. This is unfortunately not possible in a severely resource limited setting such as
South Sudan. The optimal threshold will be a compromise between sensitivity and specificity,
i.e. a threshold needs to be chosen that includes as many patients with increased risk of dying
as possible, whilst maintaining a rational use of scarce resources. Whilst our focus has been to
reduce VL mortality by identifying those patients most at risk of dying, the severity scoring
system could be a useful tool in the management of patients at lower risk. VL patients with a
low risk of dying (<3.0%), could be treated on an ambulatory basis in outpatient treatment
centres. Patients with a moderate risk of dying (3–10%) could be treated in an outpatient
department, but under close monitoring by experienced clinicians. Patients with a higher
score and thus a higher risk of dying (>10%) should be admitted as inpatients for specialised
VL care and intensive monitoring.
In this study there was no association of acute malnutrition (WHZ <-2) with death in chil-
dren and adolescents, although severe acute malnutrition (WHZ<-4) was associated with
increased risk of death. This finding is in contrast with earlier studies in South Sudan in 2004
and 1991 [15, 16]. The lack of association at less severe levels of malnutrition in our study
could be explained by improved treatment of malnourished children in an intensive therapeu-
tic feeding centre (ITFC), where malnourished children receive specialised medical and nutri-
tional care. This specialized treatment may have mediated the impact of malnutrition on VL
mortality in children, except for the very severely malnourished. In our final prediction model,
severely malnourished children would score highly for being in a state of collapse and/or pre-
senting with very low Hb levels, and would exceed the threshold for specialised care.
A finding which is in line with previous studies in South Sudan is that young age was a
strong predictor for VL mortality [15, 16]. The eleven-fold higher odds of death in children
below 2 years (compared with older children) demonstrate the vulnerability of this youngest
age group. Accordingly, age<2 years contributed 4 points, and even without additional risk fac-
tors already is at ‘moderate risk’. On the other hand, older age (>45 years), which was strongly
associated with mortality in the univariate analysis, was not retained as an independent risk fac-
tor in the multivariable regression model, contrary to earlier studies [15, 16, 22]. In these earlier
studies, most elderly patients were treated with SSG, whereas in the present study 87% of the
patients older than 45 years were treated with AmBisome [15, 16, 28]. Several studies had dem-
onstrated a high mortality in older patients due to SSG toxicity, and during those earlier studies
there was no or only limited AmBisome available [12]. Therefore in our dataset, AmBisome
may have mediated the effect of older age on VL mortality. This seems to confirm the recom-
mendation that treatment with AmBisome may be lifesaving for the elderly VL patients [9].
In contrast with two previous studies we did not find that splenomegaly was associated with
increased risk of death [15, 29]. Conversely, we found a crude inverse association of lymphade-
nopathy with risk of death (although not evident when adjusted for other risk factors). We can
think of no plausible explanation for these apparently anomalous findings.
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The mortality rate in this study cohort was much lower than in earlier studies (2.8% vs.
10.9% and 10.0%) [7, 16]. Despite the fact that the difficult context of civil war, violence and
displacement, the weak and unstable health care system was similar between this study and the
earlier studies in South Sudan [30, 31]. This may be partially explained by earlier presentation
at the Lankien hospital: more than 92% of the patients were able to present early, i.e. within
one month after onset of clinical disease, whereas only 65% of the patient were able to during
those earlier studies. As there were only 13 deaths in 527 patients presenting more than 1
month after onset of symptoms, duration of illness could not be identified as a risk factor. This
seems to support the interpretation that specific joint efforts led since 2009 by the World
Health Organisation in collaboration with Ministry of Health and nongovernmental organisa-
tions (NGOs), have been successful in achieving improved access to VL care in South Sudan
(by decentralising VL treatment services and ensuring supply of tests and drugs) [3, 30].
The main strength of our study is that it was based on a large dataset with very few patients
excluded because of missing data. Also, a robust external validation was possible, because of
the availability of MSF datasets from previous VL outbreaks in South Sudan. The study was
based on a cohort of South Sudanese patients, and therefore the predictors of death and the
severity scoring system should not be generalised to patient populations in other countries.
For example, where VL is caused by other Leishmania strains, where HIV co-infection is more
prevalent, or where resistance to SSG is more common or AmBisome is more affordable.
Another limitation is that this retrospective study was conducted with routinely collected pro-
gramme data. Therefore it may be missing out on other important risk factors that were not
included in this database, such as laboratory parameters (e.g. related to electrolyte distur-
bances, blood cell counts, or immune status). Although one third of deaths occurred within
the first 48 hours after admission, which may limit the impact of our severity scoring system
on mortality, the predictive ability and simplicity of the system means that it can be easily
operationalised and implemented in the field.
The scoring system presented in this study only includes clinical parameters and a simple
Hb lab test, and it therefore presents a practical tool that can be used in all field hospitals and
health centres in the VL endemic areas in South Sudan. Clinicians will use their clinical judge-
ment and experience to make treatment decisions, aided by the risk scoring tool. Given the
strong associations between known risk factors and mortality, it would not be ethical to
attempt a randomised trial of the severity scoring system, but we would hope to see a (contin-
ued) overall improvement in treatment outcomes in VL programmes in South Sudan until
new safe, effective, and affordable treatment becomes available for all patients.
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